Business
BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno
SUNNYVALE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the election of Mr. Marvin Slosman to its Board of Directors, effective December 2, 2025. Dr. Richard Krasno, who has served on the Board since 2016, has completed his term and departed the Board effective December 2, 2025. “We are very pleased to welcome Mr. Slosman to our Board,
About this update from Biocardia, Inc.
[{"type":"image","alt":"BioCardia, Inc.","displaySize":"","headline":null,"caption":"BioCardia, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":68,"url":"https://media.zenfs.com/en/globenewswire.com/a5e6da8ba4e1db953fe3f1e134f34300"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qoNytrtYWwAQFfByGKCPTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/a5e6da8ba4e1db953fe3f1e134f34300","width":300,"height":68}},"lazy":false},{"type":"text","content":"SUNNYVALE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the election of Mr. Marvin Slosman to its Board of Directors, effective December 2, 2025. Dr. Richard Krasno, who has served on the Board since 2016, has completed his term and departed the Board effective December 2, 2025.","length":447,"tagName":"p"},{"type":"text","content":"“We are very pleased to welcome Mr. Slosman to our Board,” said Peter Altman, Chief Executive Officer of BioCardia. “With deep expertise in the interventional cardiology sector and a strong track record in advancing breakthrough technologies from concept to commercialization, Mr. Slosman brings an exceptional understanding of regulatory pathways, global market expansion, and clinical value creation. He will be a tremendous asset as we continue to scale our portfolio and deliver innovative solutions for patients and providers.”","length":532,"tagName":"p"},{"type":"text","content":"Mr. Slosman currently serves as President, Chief Executive Officer, and Director of InspireMD, a NASDAQ listed medical device company focused on vascular and carotid-artery disease management solutions. In addition to experience as Chief Executive Officer, he has held positions as Chief Operating Officer, and senior commercial-leadership roles at major medical and healthcare companies, including Johnson & Johnson, GE Healthcare, and Baxter International Inc., helping drive commercialization and market development efforts. His background includes significant accomplishments in both public and private growth companies with expertise in regulatory pathways and approvals, strategic partnerships, product development, and operational and commercial gr...